对比分析瑞舒伐他汀与辛伐他汀对心肌梗死患者血清C反应蛋白及基质金属蛋白酶—9水平的影响
2017-03-28钟淑萍
钟淑萍

【摘要】 目的 研究心肌梗死患者应用瑞舒伐他汀和辛伐他汀对血清C反应蛋白(CRP)、基质金属蛋白酶-9(MMP-9)水平的影响。方法 86例心肌梗死患者, 随机分为甲组和乙组, 各43例。甲组患者采用瑞舒伐他汀治疗, 乙组患者采用辛伐他汀治疗。比较两组患者治疗前后血清CRP、MMP-9水平。结果 治疗前, 两组患者CRP、MMP-9水平比较差异无统计学意义(P>0.05);治疗后, 甲组患者血清CRP为(2.05±0.32)mg/L、MMP-9为(110.5±12.8)ng/L, 均低于乙组的(3.12±0.47)mg/L、(143.7±15.3)ng/L,
差异具有统计学意义(P<0.05)。结论 在心肌梗死的临床治疗中, 瑞舒伐他汀能起到更好的清除炎症因子、降低MMP-9水平的效果, 有助于促进患者的康复, 值得推广应用。
【关键词】 瑞舒伐他汀;辛伐他汀;心肌梗死;C反应蛋白;基质金属蛋白酶-9
DOI:10.14163/j.cnki.11-5547/r.2017.05.056
Comparative analysis of influence by rosuvastatin and simvastatin on serum C-reactive protein and matrix metalloproteinase-9 levels in myocardial infarction patients ZHONG Shu-ping. Guangzhou City Zengcheng District Zhengguo Health Center, Guangzhou 511390, China
【Abstract】 Objective To research influence by rosuvastatin and simvastatin on serum C-reactive protein (CRP) and matrix metalloproteinase-9 (MMP-9) levels in myocardial infarction patients. Methods A total of 86 patients with myocardial infarction were randomly divided into group A and group B, with 43 cases in each group. Group A received rosuvastatin for treatment, and group B received simvastatin for treatment. Comparison was made on serum CRP and MMP-9 levels before and after treatment between the two groups. Results Before treatment, there was no statistically significant difference of CRP and MMP-9 levels between the two groups (P>0.05). After treatment, group A had serum CRP as (2.05±0.32) mg/L and MMP-9 as (110.5±12.8) ng/L, which were all lower than (3.12±0.47) mg/L and (143.7±15.3) ng/L in group B, and their difference had statistical significance (P<0.05). Conclusion In clinical treatment of myocardial infarction, rosuvastatin provides better effect in eliminating inflammatory factor and reducing MMP-9 level. It is helpful to accelerate rehabilitation in patients, and it is worth promoting and applying.
【Key words】 Rosuvastatin; Simvastatin; Myocardial infarction; C-reactive protein; Matrix metalloproteinase-9
不少學者认为炎症反应、基质金属蛋白酶水平的变化是导致斑块不稳定的原因, 是导致心肌梗死形成的主要因素之一[1-3]。瑞舒伐他汀和辛伐他汀均具有较好的抑制炎症反应、稳定斑块效果[4, 5], 而CRP和MMP-9是评估心肌梗死患者病情严重程度、判定预后的重要指标。为探究这两种药物在心肌梗死治疗中的价值, 特开展本次研究, 对比分析两种药物对于心肌梗死患者CRP、MMP-9水平的影响, 现报告如下。
1 资料与方法
1. 1 一般资料 从本院2012年2月~2015年2月收治的心肌梗死患者中随机抽取出86例作为研究对象, 全部患者均为急性发作, 于发病24 h内入院, 排除合并外伤、活动性炎症、恶性肿瘤、肝肾功能障碍的患者, 全部患者均不对肝素类、他汀类药物过敏。将86例患者随机分为甲组和乙组, 各43例。甲组患者中男23例, 女20例, 年龄37~62岁, 平均年龄(49.6±5.3)岁;乙……
